Alchemia Of Australia Finally Set To File For Synthetic Drug Generic
This article was originally published in PharmAsia News
Executive Summary
Australia's Alchemia is looking for marketing partners now that it has overcome a three-year delay and filed for U.S. approval of its synthetic anti-clotting generic of GlaxoSmithKline's Arixtra (fondaparinux). Alchemia blamed its delay beyond the original 2006 filing target on the complexities involved in synthesizing the drug. The company expects FDA approval and marketing in the second half of this year, with Dr. Reddy's Laboratories already chosen to market the drug in India. (Click here for more